Trombolysis in acute stroke

Israel Medical Association Journal

Volumn 8, Issue 11, 2006, Pages 784-787

  Schwammenthal, Yvonne ^a,c   Tsabari, Rakefet ^a,c   Bakon, Mati ^b,c   Orion, David ^a,c   Merzeliak, Oleg ^a,c   Tanne, David ^a,c  

^a Sagol Neuroscience Center   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Reperfusion; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE;

ADULT; AGE DISTRIBUTION; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; DRUG APPROVAL; DRUG FATALITY; DRUG SAFETY; ENDOVASCULAR SURGERY; EXPERIENCE; FEMALE; HEALTH CARE SYSTEM; HOSPITAL CARE; HOSPITAL DISCHARGE; HUMAN; INDEPENDENCE; ISRAEL; MALE; MOUTH DISEASE; OUTCOME ASSESSMENT; REPERFUSION; SCORING SYSTEM; STATISTICAL MODEL; THERAPY EFFECT; TONGUE DISEASE;

ADULT; AGED; CEREBROVASCULAR ACCIDENT; FEMALE; HUMANS; ISRAEL; MALE; MEDICAL RECORDS; MIDDLE AGED; MYOCARDIAL REPERFUSION; SEVERITY OF ILLNESS INDEX; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 33751563679     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-8.
2. Furlan A, Higashida R, Wechsler L, et al., for the PROACT Investigators. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA 1999; 282:2003-11.
3. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA Stroke trials. Lancet 2004;363:768-4.
4. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the early management of patients with ischemic stroke: 2005 guidelines update a scientific statement from the stroke council of the American Heart Association/American Stroke Association. Stroke 2005;36:916-23.
5. Tanne D, Streifler JY, Gross B, Lampl Y, Bornstein NM. Guidelines for the management of acute stroke - 2005. Harefuah 2006;145:82-9, 168 (Hebrew).
6. Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation 2001;103:2897-902.
7. Saver JL. Time is brain-quantified. Stroke 2006;37:263-6.
8. Schwammenthal Y, Drescher MJ, Merzeliak O, et al. Intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke: initial Israeli experience. IMAJ 2004;6:70-4.
9. Herndon R. Handbook of Neurologic Rating Scales. New York: Demos Vermande; 1997.
10. Toni D, Lorenzano S, Puca E, Prencipe M. The SITS-MOST registry. Neurol Sci 2006;27(Suppl 3):S260-2.
11. Koton S, Schwammenthal Y, Merzeliak O, et al. Effectiveness of establishing a dedicated acute stroke unit on outcome in routine clinical practice in Israel. IMAJ 2005;7:688-93.
12. Tanne D, Goldbourt U, Koton S, et al. A national survey of acute cerebrovascular disease in Israel: burden, management, outcome and adherence to guidelines. IMAJ 2006;8:3-7
13. Grotta JC, Burgin WS, El-Mitwalli A, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001;58:2009-13.
14. Nadeau JO, Shi S, Fang J, et al. TPA use for stroke in the registry of the Canadian stroke network. Can J Neurol Sci 2005;32: 433-9.
15. Saver JL. Number needed to treat estimates incorporating effects over the entire range of clinical outcomes: novel derivation method and application to thrombolytic therapy for acute stroke. Arch Neurol 2004;61:1066-70.
16. Alexandrov AV, Molina CA, Grotta JC, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 2004;351:2170-8.
17. Hacke W, Albers G, Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005;36:66-73.
18. Furlan AJ, Eyding D, Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37:1227-31.
19. Molina CA, Saver JL. Extending reperfusion therapy for acute ischemic stroke: emerging pharmacological, mechanical, and imaging strategies. Stroke 2005;36:2311-20.
20. Tanne D, Macko RF, Lin Y, Tilley BC, Levine SR. Hemostatic activation and outcome after recombinant tissue plasminogen activator therapy for acute ischemic stroke. Stroke 2006;37:1798-804.
21. Nesbit GM, Luh G, Tien R, Barnwell SL. New and future endovascular treatment strategies for acute ischemic stroke. J Vasc Interv Radiol 2004;15:S103-10.
22. Choi JH, Bateman BT, Mangla S, et al. Endovascular recanalization therapy in acute ischemic stroke. Stroke 2006;37:419-24.
23. Smith WS, Sung G, Starkman S, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 2005;36:1432-8.
24. Hellier KD, Hampton JL, Guadagno JV, et al. Perfusion CT helps decision making for thrombolysis when there is no clear time of onset. J Neurol Neurosurg Psychiatry 2006;77:417-19.
25. Ribo M, Molina CA, Rovira A, et al. Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke 2005;36:602-6.